All 1 Debates between Jane Ellison and Pamela Nash

Thu 26th Mar 2015

Penrose Inquiry

Debate between Jane Ellison and Pamela Nash
Thursday 26th March 2015

(9 years, 7 months ago)

Commons Chamber
Read Full debate Read Hansard Text Read Debate Ministerial Extracts
Jane Ellison Portrait Jane Ellison
- Hansard - -

Of course. In my response to the Backbench business debate, I gave Members a sense of how to represent constituents as regards the latest NHS treatments. The latest treatments available for hepatitis C are of a different order of effectiveness and have many fewer side-effects than the older treatments and it is important that anyone affected is seen by a hepatologist and referred appropriately. NICE and the NHS are currently considering the new treatments.

Pamela Nash Portrait Pamela Nash (Airdrie and Shotts) (Lab)
- Hansard - - - Excerpts

The report published yesterday suggests that NHS staff were working according to the best available knowledge at the time. As chair of the all-party group on HIV and AIDS, however, I often hear about current incidents in which NHS staff do not have the best available knowledge at their fingertips. What have the Government done and what are they doing to ensure that we have a well-informed NHS? Is the Minister confident that there is not a similar tragedy brewing within the NHS today?

Jane Ellison Portrait Jane Ellison
- Hansard - -

For blood donations, the picture is thankfully very different today from the situation in the 1970s and ’80s that Lord Penrose was considering. Today, blood donations are screened for both HIV and hep C as well as a number of other infections. I recently visited the blood processing site at Colindale to see the rigorous and high-tech approach to blood safety in this country. Members can be more reassured in that regard. Of course, synthetic products are available for the treatment of all haemophilia patients for whom they are suitable. On the question of the latest knowledge, I can only reiterate that NHS England is considering a further early access policy to include patients with cirrhosis. It is aiming to have that in place in the first half of this year. Importantly, NICE guidance on the use of such therapies is also expected in the first half of this year.